Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.

Day, James W; Fox, Thomas A; Halsey, Richard; Carpenter, Ben; Kottaridis, Panagiotis D

Day, James W; Fox, Thomas A; Halsey, Richard; Carpenter, Ben; Kottaridis, Panagiotis D.

Day JW; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Fox TA; UCL Institute of Immunity and Transplantation, UCL, London, UK.
Halsey R; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Carpenter B; UCL Institute of Immunity and Transplantation, UCL, London, UK.
Kottaridis PD; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

Br J Haematol ; 190(2): e80-e83, 2020 07.

Article in English | MEDLINE | ID: covidwho-625516

Subject(s)

Coronavirus Infections/complications; Interleukin 1 Receptor Antagonist Protein/therapeutic use; Interleukin-1/antagonists & inhibitors; Leukemia/drug therapy; Pneumonia, Viral/complications; Adult; Betacoronavirus; COVID-19; Humans; Male; Pandemics; SARS-CoV-2

Keywords

acute leukaemia; haemophagocytic syndrome; immunotherapy; infection

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Leukemia / Interleukin-1 / Coronavirus Infections / Interleukin 1 Receptor Antagonist Protein Type of study: Case report / Prognostic study Topics: Long Covid / Variants Limits: Adult / Humans / Male Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.16873

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google